sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
4-Mar-2015 17:45
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 962.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 9-Dec-2014
International Journal of Infectious Diseases
Guidelines for treatment of Ebola patients are urgently needed
As the Ebola Virus Diseases epidemic continues to rage in West Africa, infectious diseases experts call attention to the striking lack of treatment guidelines. With over 16,000 total cases and more than 500 new infections reported per week, and probable underreporting of both cases and fatalities, the medical community still does not have specific approved treatment in place for Ebola, according to an editorial published in the International Journal of Infectious Diseases.

Contact: Fiona Macnab
hmsmedia@elsevier.com
44-207-424-4259
Elsevier Health Sciences

Public Release: 9-Dec-2014
Lancet Infectious Diseases
Simeprevir-based therapy offers cost-effective alternative in treatment of hepatitis C
Researchers at Penn Medicine, in collaboration with an international team, have shown that a protease inhibitor, simeprevir, along with interferon and ribavirin is as effective in treating chronic Hepatitis C virus infection as telaprevir with interferon and ribavirin, the standard of care in developing countries. Further, simeprevir proved to be simpler for patients and had fewer adverse events. The complete study is online and is scheduled to publish in January 2015 in The Lancet Infectious Diseases.
Janssen Research and Development

Contact: Lee-Ann Donegan
leeann.donegan@uphs.upenn.edu
215-349-5660
University of Pennsylvania School of Medicine

Public Release: 9-Dec-2014
Bayer and DNDi sign agreement to develop an oral treatment for river blindness
Bayer HealthCare and the Drugs for Neglected Diseases initiative have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

Contact: Violaine Dällenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative

Public Release: 9-Dec-2014
ACS Nano
Nanotechnology against malaria parasites
Malaria parasites invade human red blood cells; they then disrupt them and infect others. Researchers at the University of Basel and the Swiss Tropical and Public Health Institute have now developed so-called nanomimics of host cell membranes that trick the parasites. This could lead to novel treatment and vaccination strategies in the fight against malaria and other infectious diseases. Their research results have been published in the scientific journal ACS Nano.

Contact: Olivia Poisson
olivia.poisson@unibas.ch
University of Basel

Public Release: 9-Dec-2014
Genome Research
Using genome sequencing to track MRSA in under-resourced hospitals
Whole genome sequencing of MRSA from a hospital in Asia has demonstrated patterns of transmission in a resource-limited setting, where formal screening procedures are not feasible.

Contact: Sarah Collins
sarah.collins@admin.cam.ac.uk
44-012-237-65542
University of Cambridge

Public Release: 9-Dec-2014
International Journal of Epidemiology
Experts call for faster mobilization of 'overlooked' survivors to contain Ebola epidemic
In an editorial published online today in the International Journal of Epidemiology, experts from the Departments of Psychiatry and Epidemiology at Columbia University, New York, are calling for survivors of the Ebola epidemic to be mobilised in a bid to hasten containment of the disease.

Contact: Kirsty Doole
kirsty.doole@oup.com
01-865-355-439
Oxford University Press

Public Release: 9-Dec-2014
Genome Research
Genome sequencing traces MRSA spread in high transmission setting
Methicillin-resistant Staphylococcus aureus is a common cause of hospital-acquired infections, with the largest burden of infections occurring in under-resourced hospitals. While genome sequencing has previously been applied in well-resourced clinical settings to track the spread of MRSA, transmission dynamics in settings with limited infection control is unknown. In a study published online today in Genome Research, researchers used genome sequencing to understand the spread of MRSA in a resource-limited hospital with high transmission rates.
Medical Research Council, Wellcome Trust, NIHR Cambridge Biomedical Research Centre

Contact: Peggy Calicchia
calicchi@cshl.edu
516-422-4012
Cold Spring Harbor Laboratory

Public Release: 8-Dec-2014
Annals of Global Health
Asbestos: An ongoing challenge to global health
Challenges to global health can evolve from policies and decisions that take years or decades to unfold. An article in the current issue of the Annals of Global Health describes the current state of asbestos use worldwide, a story that began over 100 years ago, and the real and contrived controversies regarding asbestos.

Contact: Eileen Leahy
hmsmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 8-Dec-2014
Each dollar spent on kids' nutrition can yield more than $100 later
There are strong economic incentives for governments to invest in early childhood nutrition, reports a new paper from the University of Waterloo and Cornell University. Published for the Copenhagen Consensus Centre, the paper reveals that every dollar spent on nutrition during the first 1,000 days of a child's life can provide a country up to $166 in future earnings.

Contact: Pamela Smyth
psmyth@uwaterloo.ca
519-888-4777
University of Waterloo

Public Release: 8-Dec-2014
Rapid Ebola test is focus of NIH grant to Rutgers scientist
Rutgers researcher David Alland, working with the California biotechnology company Cepheid, has received a grant of nearly $640,000 from the National Institutes of Health to develop a rapid test to diagnose Ebola as well as other viruses that can cause symptoms similar to Ebola. Alland and Cepheid previously used technology similar to the planned Ebola test to develop a rapid test for tuberculosis that is now widely used in impoverished areas of the world.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Rob Forman
robert.forman@rutgers.edu
973-972-7276
Rutgers University

Public Release: 8-Dec-2014
Lancet
Combining insecticide sprays and bed nets 'no more effective' in cutting malaria
There is no need to spray insecticide on walls for malaria control when people sleep under treated bed nets, according to new research by Durham University and the Medical Research Council's Unit in The Gambia.
Medical Research Council

Contact: Steve Lindsay
s.w.lindsay@durham.ac.uk
44-191-334-1291
Durham University

Public Release: 8-Dec-2014
Nature Cell Biology
A pill for obesity?
Harvard Stem Cell Institute researchers at Harvard and Massachusetts General Hospital have taken what they are describing as 'the first step toward a pill that can replace the treadmill' for the control of obesity -- though it of course would not provide all the additional benefits of exercise. The researchers have already identified two compounds that can accomplish that in human cells.

Contact: B. D. Colen
bd_colen@harvard.edu
617-413-1224
Harvard University

Public Release: 5-Dec-2014
International Journal of Biomedical Engineering and Technology
Stick out your tongue
The tongue can betray signs of illness, which combined with other symptoms such as a cough, fever, presence of jaundice, headache or bowel habits, can help a physician offer a diagnosis. For people in remote areas who do not have ready access to a physician, a new diagnostic system is reported in the International Journal of Biomedical Engineering and Technology that works to combine the soft inputs of described symptoms with a digital analysis of an image of the patient's tongue.

Contact: Albert Ang
press@inderscience.com
Inderscience Publishers

Public Release: 4-Dec-2014
Nature Communications
UCLA study: To stop spread of HIV, African governments should target hot zones
To stop the spread of HIV in Africa, researchers at UCLA, using a complex mathematical model, have developed a strategy that focuses on targeting 'hot zones,' areas where the risk of HIV infection is much higher than the national average.

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles

Public Release: 4-Dec-2014
Ebola rapid response
The National Science Foundation has awarded the first of a number of rapid response grants to advance fundamental Ebola research. The grants will support researchers seeking to answer important questions about the virus's fundamental nature, how it interacts with other substances, how it spreads, and how communication and perception affect public safety during an epidemic.
National Science Foundation

Contact: Sarah Bates
sabates@nsf.gov
703-292-7738
National Science Foundation

Public Release: 4-Dec-2014
PLOS Pathogens
Blood pressure build-up from white blood cells may cause cerebral malaria death
Intracranial hypertension -- increased blood pressure inside the head -- can predict a child's risk of death from malaria. A study published on Dec. 4 in PLOS Pathogens reports that accumulation of white blood cells impairs the blood flow out of the brain and causes blood pressure increases in mice with experimentally induced cerebral malaria.
Dana Foundation, National Institutes of Health

Contact: Ute Frevert
ute.frevert@nyumc.edu
212-263-6755
PLOS

Public Release: 4-Dec-2014
Cell
Friendly bacteria are protective against malaria
In a breakthrough study to be published on the Dec. 4 issue of the prestigious scientific journal Cell, a research team led by Miguel Soares at the Instituto Gulbenkian de Ciencia discovered that specific bacterial components in the human gut microbiota can trigger a natural defense mechanism that is highly protective against malaria transmission.
Bill and Melinda Gates Foundation, Fundano para a Ciencia e a Tecnologia, European Research Council

Contact: Ana Mena
anamena@igc.gulbenkian.pt
351-214-407-959
Instituto Gulbenkian de Ciencia

Public Release: 3-Dec-2014
Parasite researcher wins international malaria medal
Melbourne researcher professor Alan Cowman has won the Sornchai Looareesuwan Medal 2014 for his significant contributions to understanding how the malaria parasite causes disease and for his search for potential malaria vaccines.

Contact: Alan Gill
gill.a@wehi.edu.au
61-393-452-719
Walter and Eliza Hall Institute

Public Release: 3-Dec-2014
Volunteers can now help scientists seek Ebola cure in their (computer's) spare time
Beginning today, anyone can download a safe and free app that will put their computer or Android-based mobile device to work to form a virtual supercomputer to help The Scripps Research Institute screen millions of chemical compounds to identify new drug leads for treating Ebola. Meanwhile, the devices will remain fully available for normal use by their owners.

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 2-Dec-2014
Novel nanoparticle technology to be used to screen for Ebola virus in saliva
Ceres Nanosciences will work with George Mason University and the United States Army Medical Research Institutes of Infectious Diseases to assess the ability of the Nanotrap technology to develop a more sensitive and safer Ebola virus detection method that uses saliva instead of blood.
Bill & Melinda Gates Foundation

Contact: Michele McDonald
mmcdon15@gmu.edu
703-993-8781
George Mason University

Public Release: 1-Dec-2014
Transfusion
Experts question aspects of certain Ebola guidelines
Various guidelines for caring for patients infected with Ebola virus are being issued from different national and state public health authorities, professional societies, and individual hospitals. Experts are questioning aspects of some of the guidelines that go beyond current CDC recommendations, especially those that call for suspending certain routine lab tests.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 29-Nov-2014
Canada funds 11 new global health innovations in La Francophonie member states
Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie. All new projects excel in boldness and creativity and aim to address pressing health challenges, such as malaria, malnutrition and sanitation. They will help to improve maternal, newborn and child health, Canada's top development priority.
Grand Challenges Canada

Contact: Lode Roels
lode.roels@grandchallenges.ca
416-673-6570
Grand Challenges Canada

Public Release: 27-Nov-2014
Science
Secret of tetanus toxicity offers new way to treat motor neuron disease
The way that tetanus neurotoxin enters nerve cells has been discovered by UCL scientists, who showed that this process can be blocked, offering a potential therapeutic intervention for tetanus. This newly-discovered pathway could be exploited to deliver therapies to the nervous system, opening up a whole new way to treat neurological disorders such as motor neuron disease and peripheral neuropathies.
Medical Research Council, Cancer Research UK

Contact: Siobhan Pipa
siobhan.pipa@ucl.ac.uk
44-207-679-9041
University College London

Public Release: 26-Nov-2014
New England Journal of Medicine
NIAID/GSK experimental Ebola vaccine appears safe, prompts immune response
An experimental vaccine to prevent Ebola virus disease was well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial conducted by researchers from the National Institutes of Health. The candidate vaccine, which was co-developed by the NIH's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, was tested at the NIH Clinical Center in Bethesda, Md.
NIH/National Institute of Allergy and Infectious Disease, GlaxoSmithKline

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 25-Nov-2014
Vaccine
Powdered measles vaccine found safe in early clinical trials
A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published Nov. 28 in the journal Vaccine. The paper is now available online.
National Institutes of Health, Bill and Melinda Gates Foundation

Contact: Robert Sievers
Bob.Sievers@colorado.edu
303-492-7943
University of Colorado at Boulder

Showing releases 126-150 out of 962.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>